SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-23-029989
Filing Date
2023-02-09
Accepted
2023-02-09 16:04:56
Documents
2
Group Members
ANSBERT GADICKEBIOIMPACT CAPITAL LLCONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d317632dsc13ga.htm SC 13G/A 82542
2 EX-99.A d317632dex99a.htm EX-99.A 7098
  Complete submission text file 0001193125-23-029989.txt   91344
Mailing Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130
Business Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 858-369-7100
MEI Pharma, Inc. (Subject) CIK: 0001262104 (see all company filings)

IRS No.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SC 13G/A | Act: 34 | File No.: 005-79594 | Film No.: 23606166
SIC: 2834 Pharmaceutical Preparations

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 617-425-9200
UBS Oncology Impact Fund L.P. (Filed by) CIK: 0001691428 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G/A